Naltrexone extended-release plus bupropion extended-release for treatment of obesity

JAMA. 2015 Mar;313(12):1213-4. doi: 10.1001/jama.2015.1617.

Authors

Susan Z Yanovski¹, Jack A Yanovski²

Affiliations

¹ Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
² Section on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

No abstract available

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Anti-Obesity Agents / adverse effects
Anti-Obesity Agents / therapeutic use*
Bupropion / adverse effects
Bupropion / therapeutic use*
Drug Combinations
Humans
Naltrexone / adverse effects
Naltrexone / therapeutic use*
Obesity / drug therapy*
Weight Loss

Substances

Anti-Obesity Agents
Drug Combinations
bupropion hydrochloride, naltrexone hydrochoride drug combination
Bupropion
Naltrexone

Grants and funding